Paediatric Investigation Plans: Regulatory Strategies for Global Compliance and Drug Development

Introduction to Paediatric Investigation Plans (PIP)

A Paediatric Investigation Plan (PIP) is a comprehensive development program designed to ensure that medicines are appropriately studied in children. Introduced under the EU Paediatric Regulation (EC No 1901/2006), PIPs are mandatory for new medicines seeking marketing authorization in the European Union. Similar requirements exist in the US (FDA’s Pediatric Study Plan, PSP) and are emerging in India under CDSCO guidelines. The EMA’s Paediatric Committee (PDCO) reviews and approves PIPs, ensuring paediatric needs are addressed early in drug development.

By 2025, paediatric development has become a central regulatory expectation, driven by global harmonization efforts and the ethical imperative to provide safe, effective medicines for children. For RA professionals, mastering PIP requirements is essential for global submission readiness.

Key Concepts and Regulatory Definitions

Several terms underpin PIP regulatory frameworks:

• PIP: EU-required plan for studying medicines in children, approved by PDCO.
• PSP: Pediatric Study Plan required by the FDA under the Pediatric Research Equity Act (PREA).
• Waiver: Regulatory exemption from PIP/PSP when paediatric studies are inappropriate (e.g., diseases not affecting children).
• Deferral: Permission to postpone paediatric studies until after initial adult approvals.
• PDCO: EMA Paediatric Committee responsible for reviewing PIPs.

These concepts guide PIP submissions and determine obligations in different jurisdictions.

Global Regulatory Frameworks for PIP Compliance

PIP and paediatric study obligations differ by region:

• EU (EMA): Mandatory PIP submission for all new marketing authorization applications (MAAs), line extensions, or new indications. Waivers and deferrals possible but must be justified.
• US (FDA): Pediatric Study Plans required under PREA, aligned with the FDA’s Division of Pediatrics and Maternal Health. Waivers/deferrals possible under BPCA incentives.
• India (CDSCO): Draft guidance mandates paediatric clinical trial planning for selected therapeutic areas, with ethics committee oversight.
• ROW Markets: Japan (PMDA) and Canada (Health Canada) encourage paediatric study submissions for global harmonization.

RA professionals must ensure alignment of PIP/PSP strategies with global submissions to avoid approval delays.

Processes and Workflow for Paediatric Investigation Plans

The PIP process involves a multi-step workflow:

1. Early Planning: Initiate paediatric strategy during preclinical/early clinical development.
2. Draft PIP Preparation: Develop paediatric study protocols, age group justifications, and deferral/waiver requests.
3. Submission to EMA: Submit PIP dossier to PDCO before completion of adult pivotal studies.
4. PDCO Review: Receive feedback, revise plans, and secure agreement on PIP content.
5. Implementation: Conduct agreed paediatric trials in alignment with deferral timelines.
6. Final Compliance Check: EMA verifies completion of PIP obligations before granting full marketing authorization.
7. Global Integration: Align PIP with FDA PSP and CDSCO paediatric trial expectations for global harmonization.

This workflow ensures paediatric requirements are integrated into overall development strategies.

Case Study 1: EMA PIP Approval

Case: A biotech company developing a rare disease therapy submitted a PIP to EMA in 2022.

• Challenge: Limited data on paediatric population and small patient numbers.
• Action: Provided extrapolation from adult data and sought a partial waiver for infants.
• Outcome: PDCO approved PIP with deferred studies for older children.
• Lesson Learned: Early engagement with PDCO increases chances of successful PIP approval.

Case Study 2: FDA Pediatric Study Plan

Case: An oncology drug developer filed an FDA PSP in 2023 under PREA requirements.

• Challenge: FDA required studies in adolescents despite limited prevalence.
• Action: Submitted revised PSP including adolescent cohort and age-appropriate formulations.
• Outcome: PSP accepted, aligning FDA and EMA paediatric requirements.
• Lesson Learned: Aligning PSP with PIP reduces duplication and accelerates global approvals.

Tools, Templates, and Systems Used

Paediatric planning requires specialized resources:

• EMA PIP Templates: Official forms detailing paediatric study protocols and waiver requests.
• FDA PSP Guidance: Structured templates for pediatric study plans under PREA.
• Extrapolation Models: Statistical tools for applying adult efficacy data to paediatric populations.
• Clinical Trial Protocol Templates: Age-appropriate designs for pediatric cohorts.
• RIM Systems: Platforms to manage PIP/PSP submissions across global agencies.

These tools improve dossier quality, harmonization, and inspection readiness for paediatric submissions.

Common Challenges and Best Practices

PIP submissions often encounter challenges:

• Small Populations: Rare disease studies struggle with low paediatric enrolment.
• Ethical Concerns: Balancing study requirements with child safety.
• Regulatory Variability: Differences in PIP vs PSP vs CDSCO frameworks complicate global strategy.
• Formulation Development: Creating age-appropriate dosage forms increases complexity.

Best practices include engaging EMA PDCO and FDA early, using extrapolation where possible, requesting justified waivers/deferrals, and aligning protocols with international ethics standards.

Latest Updates and Strategic Insights

As of 2025, paediatric regulatory strategies are evolving rapidly:

• Extrapolation Advances: EMA and FDA increasingly accept model-based extrapolation to minimize paediatric trial burden.
• Global Harmonization: ICH Pediatric Working Group promoting unified standards for PIP/PSP submissions.
• Digital Tools: AI-driven patient recruitment and e-consent platforms supporting paediatric trials.
• Paediatric Incentives: Additional exclusivity periods granted for completing paediatric obligations.
• Transparency: Public disclosure of PIP compliance decisions to improve trust in paediatric drug development.

Strategically, RA professionals must align paediatric strategies with global harmonization efforts and use innovative trial designs to ensure regulatory compliance and patient safety.

Conclusion

Paediatric Investigation Plans are a cornerstone of modern regulatory frameworks, ensuring that children have access to safe, effective medicines. By mastering EMA, FDA, and CDSCO requirements, RA professionals can integrate paediatric strategies into global submissions, secure incentives, and advance rare and common disease treatments for younger populations. In 2025 and beyond, PIPs will remain central to ethical, sustainable, and compliant drug development.